ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Gilead Sciences at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Gilead Sciences takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8063. Its sessions focus on antibody-drug conjugates in breast and gynaecological cancers and on evidence for lung cancer treatment decisions. They cover treatment strategies for advanced triple-negative breast cancer and using real-world data to compare outcomes.
| Organization | ESMO 2026 Attendance |
|---|---|
US biopharmaceutical company whose oncology unit, with cell-therapy arm Kite, markets antibody-drug conjugates and CAR T therapies. | Booth Exhibiting at Booth 8063 · Gilead and Kite Oncology Poster Fri Oct 23 13:00–15:00 Extending RWD–based external control arms from hematologic to lung malignancies for clinical and regulatory decision-making Haematological malignanciesLung & thoracic cancers Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 18:30–20:00 Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions Breast cancerGynaecological cancers |
Find decision makers at Gilead Sciences
Tell us what you sell and we’ll find the people at Gilead Sciences most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction